IQVIA Holdings Inc

IQVIA’s steady rise in a volatile life‑sciences tech market hinges on AI‑powered data integration, patient‑retention analytics, and blockchain‑enabled compliance, driving 6% revenue growth and 24% EBITDA margin toward 2026.

IQVIA refines debt, cuts interest, and faces Belgian regulatory probe—boosting margins and market‑access plans while navigating competition scrutiny.

IQVIA Holdings Inc. stays ahead in health‑care by combining clinical services, real‑world analytics, and patient‑retention tools—leveraging data science to boost drug development, market access, and personalized medicine.

TD Cowen downgrades IQVIA to Hold but lifts its target to $65, reflecting a cautious yet optimistic view amid life‑sciences volatility and macro‑economic risks.

IQVIA Holdings Inc. reports record free-cash flow of $772 million in Q3 FY 2025, driven by AI-driven growth and strategic initiatives, positioning the company for continued success in the life-sciences consulting sector.

IQVIA Holdings Inc has announced a leadership transition, with CFO Ron Bruehlman retiring and being replaced by Michael Fedock, who will take over as CFO in February 2026.

IQVIA Holdings Inc. has formed two significant partnerships with Flagship Pioneering and Veeva, aiming to accelerate breakthroughs and drive innovation in the life sciences industry.

IQVIA Holdings Inc has formed strategic partnerships with Flagship Pioneering and Veeva, positioning itself as a leader in the life sciences industry with a focus on driving innovation and growth.

IQVIA Holdings Inc. has seen a moderate increase in its stock price, driven by its strategic plan and strong position in the life sciences tools and services industry.

IQVIA Holdings Inc. has seen improved stock performance and a strategic partnership with Veeva Systems, a leading life sciences software provider, to enhance clinical and commercial efficiency.